zoledronic acid has been researched along with Deficiency, Magnesium in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cull, G; Henley, D; Kaye, J; Walsh, J | 1 |
| Cornford, P; Manikandan, R; Mistry, R; Philip, J | 1 |
| Lipton, A; Saad, F | 1 |
3 other study(ies) available for zoledronic acid and Deficiency, Magnesium
| Article | Year |
|---|---|
Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
Topics: Acute Kidney Injury; Aged; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Diphosphonates; Fatal Outcome; Female; Humans; Hypocalcemia; Imidazoles; Injections, Intravenous; Magnesium Deficiency; Male; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2005 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Urogenital Neoplasms; Zoledronic Acid | 2006 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Male; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2006 |